Article

Generation of a PARPi-sensitive homozygous BRCA1-methylated OVCAR8 cell line using targeted CRISPR gene editing

2024-09-25

Abstract excerpt

Up to 17% of high grade serous ovarian carcinomas (HGSOC) harbour BRCA1 promoter methylation (meBRCA1), making them susceptible to treatment with targeted PARP inhibitor (PARPi) therapy. Unfortunately, meBRCA1 loss can be acquired following PARPi or platinum chemotherapy, resulting in BRCA1 re–expression and PARPi resistance. Our understanding of meBRCA1 stability in HGSOC is currently limited, in part due to a pa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: febf8faf-970b-516a-a4fe-83f97fd611fc
DOI: 10.1101/2024.09.23.614644

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Generation of a PARPi-sensitive homozygous BRCA1-methylated OVCAR8 cell line using targeted CRISPR gene editingDOI 10.1101/2024.09.23.614644Read

Genomic alterations enable <i>BRCA1</i> methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancerSemantic proximity Read

Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instabilitySemantic proximity Read

Rethinking ovarian cancer III: the past decade and future directions.Semantic proximity Read

Demethylating agents drive PARP inhibitor resistance in ovarian carcinomas with BRCA1 gene silencingSemantic proximity Read

Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cellsSemantic proximity Read

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaSemantic proximity Read

CRISPR/Cas9-Mediated <i>Trp53</i> and <i>Brca2</i> Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous CarcinomaSemantic proximity Read

High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions.Semantic proximity Read

Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapySemantic proximity Read

Homologous Recombination Proficiency in High-Grade Serous Epithelial Ovarian Cancer Tumors: The Dark Side of the MoonSemantic proximity Read

Concurrent RB1 loss and<i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaSemantic proximity Read

Exploiting epigenetic dependencies in ovarian cancer therapySemantic proximity Read